×

Biotech and Pharmaceuticals Medicine

  • "Golodirsen does appear to be a more proficient exon skipper than Exondys 51," Leerink analyst Joseph Schwartz wrote in a client note. Exondys 51 is Sarepta's other DMD drug that was approved in September last year after the U.S. Food and Drug Administration bowed to patient pressure and went against the recommendation of its top scientists and a panel of...

  • Sept 6- U.S. drug developer Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal in a late-stage study by prolonging the time patients lived without their disease worsening. Shares of Verastem rose 30 percent to $5.00 in premarket trading. There will be about 62,000 new cases of leukemia in the United States this year, of...

  • Sept 6- Patients taking Roche's targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer's Xalkori, according to new clinical trial data. The results, which will be presented at the Sept. 8-12 European Society for Medical Oncology congress in Madrid, reinforce Alecensa's position in an increasingly...

  • Sept 6- Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study. The drug, duvelisib, showed a superior progression free survival rate than the current standard of care, ofatumumab, when tested on patients suffering from cancers that affect cells of the immune system, the company said.

  • Sept 6- Patients taking Roche's targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer's Xalkori, new clinical trial data show. The results, which will be presented at the Sept. 8-12 European Society for Medical Oncology congress in Madrid, reinforce Alecensa's position in an increasingly...

  • Insmed soars on positive lung drug study results

    CNBC's Meg Tirrell reports the latest on shares of Insmed and how the stock is more than doubling today.

  • Sept 5- Medical device maker Teleflex Inc said on Tuesday it would buy privately held NeoTract Inc to strengthen its portfolio of urology devices in its second billion-dollar deal in the past nine months. The company's revenue is expected to be between $115 million and $120 million this year, compared with about $51 million in 2016, and is estimated to increase...

  • Sept 5- Medical device maker Teleflex Inc said on Tuesday it would buy privately-held NeoTract Inc in a deal valued at up to $1.1 billion to strengthen its portfolio of urology devices. The company's devices are used in urology, cardiac, respiratory and emergency care, and in December last year it strengthened its coronary and vascular business with the $1...

  • LONDON, Sept 5- French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment similar to Novartis's recently approved Kymriah, has been forced to suspend testing following a patient death. Cellectis said on Tuesday it was working closely with the U.S. Food and Drug Administration in order to resume trials with a lower dose of...

  • Sept 1- The U.S. Food and Drug Administration on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia, re-clearing a drug that had been pulled off the market in 2010.. The FDA said the drug has a boxed warning as it may cause severe or fatal liver damage, including blockage of veins in the liver. Friday's approval includes a...

  • Jonathan Rupert, Distinctive Surfaces

    "Every major company ... in America has people in recovery," acting White House drug czar Richard Baum told CNBC.

  • Sept 1- The U.S. Food and Drug Administration on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia. The FDA said the drug has a boxed warning as it may cause severe or fatal liver damage, including blockage of veins in the liver. Friday's approval includes a lower recommended dose, a different dosing schedule and a new...

  • Sept 1- The U.S. Food and Drug Administration on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia. The drug was cleared to treat adults with newly diagnosed AML whose tumors express the CD33 antigen, as well as patients aged 2 years and older with CD33-positive AML who have relapsed, or did respond to initial treatment.

  • WASHINGTON, Aug 31- The U.S. Environmental Protection Agency said on Thursday that floodwaters from Tropical Storm Harvey could contain bacteria and other disease agents as sewers overflow. In a joint statement with the Texas Commission on Environmental Quality, the EPA said precautions should be taken by anyone involved in cleanups including boiling...

  • EPA SAYS HARVEY'S FLOODWATERS MAY CONTAIN MANY HAZARDS INCLUDING BACTERIA AND OTHER DISEASE AGENTS.

  • There are now more overweight people than underweight in the world for the first time ever.

    Millions of Americans are at risk for type 2 diabetes and don't know it, leading to a big push by doctors and the CDC to tackle prediabetes.

  • LONDON, Aug 31- After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease in different ways. The British drugmaker has already said the studies, known as PACIFIC and FLAURA, met their pre-defined goals but the exact...

  • Aug 30- Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers. The approval was widely expected after an FDA advisory panel last month unanimously recommended the action.

  • PRICE OF $475,000 FOR KYMRIAH GENE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.

  • Aug 30- The U.S. Food and Drug Administration on Wednesday gave a green light to Novartis AG's leukemia treatment, marking the first time that a highly anticipated new type of potent gene-modifying immunotherapy has gained approval in the United States. "Were entering a new frontier in medical innovation with the ability to reprogram a patients own cells to...